Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

NCT04147650 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

508

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndrome
Keratoconjunctivitis Sicca

Interventions

DRUG: 0.05% Voclosporin Ophthalmic Solution (VOS)
DRUG: 0.10% VOS
DRUG: 0.20% VOS
DRUG: Vehicle Ophthalmic Solution

Sponsor

Aurinia Pharmaceuticals Inc.